Open AccessDiagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study
Author(s) -
Maud Lemoine,
Lambert Assoumou,
Stéphane De Wit,
PierreMarie Girard,
Marc Antoine Valantin,
Christine Katlama,
Coca Necsoi,
Pauline Campa,
Anja D. Huefner,
Julian Schulze zur Wiesch,
Hayette Rougier,
JeanPhilippe Bastard,
Hartmut Stocker,
Stefan Mauss,
Lawrence Serfaty,
Vlad Ratziu,
Y. Menu,
Jérôme Schlué,
Georg M. N. Behrens,
Pierre Bédossa,
Jacqueline Capeau,
Patrick Ingiliz,
Dominique Costagliola
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001936
Subject(s) - nonalcoholic fatty liver disease , medicine , steatosis , gastroenterology , liver biopsy , fibrosis , fatty liver , body mass index , receiver operating characteristic , biopsy , disease
HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver disease. Noninvasive tests of steatosis, nonalcoholic steatohepatitis (NASH), and fibrosis have been poorly assessed in this population. Using liver biopsy (LB) as a reference, we assessed the accuracy of noninvasive methods for their respective diagnosis: magnetic resonance imaging proton-density-fat-fraction (MRI-PDFF), FibroScan/controlled attenuation parameter (CAP), and biochemical tests.